Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation

CONCLUSION: These findings suggest that reducing the pre-infusion MRD could serve as an effective treatment strategy to enhance the outcomes of CAR T-cell therapy.PMID:38429221 | DOI:10.1016/j.clml.2024.02.002

Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Qianwen Shang Lian Xue Aidong Lu Yueping Jia YingXi Zuo Huimin Zeng Leping Zhang Source Type: research